IVX037

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

Currently in clinical trials for colorectal cancer, IVX037 is being evaluated as a potential treatment option for patients who have progressed on standard therapies; its efficacy and safety are under investigation to determine its role in the management of advanced colorectal cancer.

Mechanism of Action

IVX037 is an investigational drug that targets the Wnt signaling pathway, which is frequently dysregulated in colorectal cancer; it inhibits beta-catenin stabilization and subsequent gene transcription.

Side Effects

Fatigue; nausea; diarrhea; neutropenia; thrombocytopenia

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT05427487 Phase 1
Recruiting
Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours
Australia

Quick Info

CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
771 trials
Leucovorin
Other Medications
631 trials
Trifluridine
Other Medications
45 trials
Paclitaxel
Other Medications
43 trials
Cyclophosphamid
Other Medications
40 trials
Cyclophosphamide
Other Medications
39 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.